Background: Tau aggregation inhibitors could treat Alzheimer disease.Results: Stable reduced forms of leucomethylthioninium (LMTX®) are active in blocking prion-like Tau aggregation in novel cellular models.Conclusion: The intracellular Ki (0.12 μm) is comparable with brain levels required for clinical benefit.Significance: LMTX® could treat Alzheimer disease.

The presence of five-membered chelating rings derived from the iminic and aminic pendant arms in dinuclear nickel() complexes of asymmetric compartmental ligands gives rise to syn-syn bidentate ethanoate bridging in these complexes whereas the introduction of a six-membered chelating ring at the iminic binding site induces an ethanoate shift generating a monodentate bridging ethanoate group. DALTON

No abstract

The asymmetric di-aminic compartmental ligand HL5 forms a tetranuclear nickel(II) complex in which the core is assembled from two confacial bioctahedra [Ni...Ni, approximately 2.90 A]; the open faces of the bioctahedra are joined at the O atoms of two mu-cresolato bridges [Ni...Ni, 3.72 A], and the shared faces of the bioctahedra are linked by a tetradentate (mu 4, eta 2)-perchlorate anion and by an unusual tetradentate (mu 4, eta 2)-[H3O2]-bridge.

No abstract